Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 3/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797521 | 0.93 | KCNH2 (0.44) | KCNH2HTR1ASLC6A4OPRM1LMNA | |
| SCHEMBL2794566 | 0.93 | KCNH2 (0.44) | KCNH2HTR1ASLC6A4LMNAUBE2M | |
| SCHEMBL2798556 | 0.93 | KCNH2 (0.45) | KCNH2HTR1ASLC6A4LMNAUBE2M | |
| SCHEMBL12000080 | 0.92 | UBE2M (0.37) | KCNH2OPRM1LMNAUBE2MDCUN1D1 | |
| SCHEMBL2796965 | 0.91 | KCNH2 (0.44) | KCNH2HTR1ASLC6A4LMNAUBE2M | |
| SCHEMBL5036618 | 0.91 | KCNH2 (0.47) | KCNH2HTR1ASLC6A4OPRM1LMNA | |
| SCHEMBL2798296 | 0.91 | KCNH2 (0.42) | KCNH2HTR1ASLC6A4LMNAUBE2M | |
| SCHEMBL12001963 | 0.90 | KCNH2 (0.45) | KCNH2HTR1ASLC6A4OPRM1LMNA | |
| SCHEMBL2796266 | 0.90 | KCNH2 (0.53) | KCNH2HTR1ASLC6A4OPRM1LMNA | |
| SCHEMBL2798529 | 0.90 | KCNH2 (0.45) | KCNH2HTR1ASLC6A4MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | KCNH2 578/4885HTR1A 3839/4885SLC6A4 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.